Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Bögemann

Showing results (31-40 of 100) with videos related to

Pageof 10
Sort By:
Nuklearmedizin. Nuclear Medicine|August 29, 2024
Prognostic value of pretherapeutic 68Ga-PSMA-11-PET based imaging parameters in mCRPC patients treated with PSMA radioligandsLaya Rahbar Nikoukar, Robert Seifert, David Ventura, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 16, 2018
<sup>18</sup>F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kineticsKambiz Rahbar, Ali Afshar-Oromieh, Martin Bögemann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 21, 2018
Diagnostic performance of <sup>18</sup>F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancerKambiz Rahbar, Ali Afshar-Oromieh, Robert Seifert, et al.
Urologic Oncology|June 5, 2014
Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomyOkyaz Eminaga, Martin Bögemann, Bernhard Breil, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 19, 2017
<sup>177</sup>Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancerAxel Bräuer, Lena Sophie Grubert, Wolfgang Roll, et al.
Clinical Genitourinary Cancer|November 6, 2025
Real-World Experience With Lenvatinib Plus Everolimus (LEN+EVE) in Patients With Pretreated Advanced Renal Cell Carcinoma (RELEVANCE): A Retrospective, Multicenter Case SeriesHendrik Eggers, Ramona Stelmacher, Martin Bögemann, et al.
Cancer Cell International|August 27, 2025
Molecular analysis of androgen receptor splice variant AR-V3 reveals eminent ambiguity regarding activity and clinical utilityNeele Wüstmann, Verena Humberg, Julia Vieler, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|October 2, 2025
Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancerNeele Wüstmann, Julissa Reimann, Julia Vieler, et al.
European Urology Focus|January 23, 2021
Prostate-specific Membrane Antigen-based Imaging of Castration-resistant Prostate CancerManuel Weber, Boris Hadaschik, Justin Ferdinandus, et al.
Oncotarget|November 21, 2017
Comparison of isolation platforms for detection of circulating renal cell carcinoma cellsYvonne Maertens, Verena Humberg, Franziska Erlmeier, et al.
Pageof 10

Showing results (31-40 of 100) with videos related to

Sort By:
Pageof 10
Nuklearmedizin. Nuclear Medicine|August 29, 2024
Prognostic value of pretherapeutic 68Ga-PSMA-11-PET based imaging parameters in mCRPC patients treated with PSMA radioligandsLaya Rahbar Nikoukar, Robert Seifert, David Ventura, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 16, 2018
<sup>18</sup>F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kineticsKambiz Rahbar, Ali Afshar-Oromieh, Martin Bögemann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 21, 2018
Diagnostic performance of <sup>18</sup>F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancerKambiz Rahbar, Ali Afshar-Oromieh, Robert Seifert, et al.
Urologic Oncology|June 5, 2014
Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomyOkyaz Eminaga, Martin Bögemann, Bernhard Breil, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 19, 2017
<sup>177</sup>Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancerAxel Bräuer, Lena Sophie Grubert, Wolfgang Roll, et al.
Clinical Genitourinary Cancer|November 6, 2025
Real-World Experience With Lenvatinib Plus Everolimus (LEN+EVE) in Patients With Pretreated Advanced Renal Cell Carcinoma (RELEVANCE): A Retrospective, Multicenter Case SeriesHendrik Eggers, Ramona Stelmacher, Martin Bögemann, et al.
Cancer Cell International|August 27, 2025
Molecular analysis of androgen receptor splice variant AR-V3 reveals eminent ambiguity regarding activity and clinical utilityNeele Wüstmann, Verena Humberg, Julia Vieler, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|October 2, 2025
Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancerNeele Wüstmann, Julissa Reimann, Julia Vieler, et al.
European Urology Focus|January 23, 2021
Prostate-specific Membrane Antigen-based Imaging of Castration-resistant Prostate CancerManuel Weber, Boris Hadaschik, Justin Ferdinandus, et al.
Oncotarget|November 21, 2017
Comparison of isolation platforms for detection of circulating renal cell carcinoma cellsYvonne Maertens, Verena Humberg, Franziska Erlmeier, et al.
Pageof 10